JP2019533442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533442A5 JP2019533442A5 JP2019518063A JP2019518063A JP2019533442A5 JP 2019533442 A5 JP2019533442 A5 JP 2019533442A5 JP 2019518063 A JP2019518063 A JP 2019518063A JP 2019518063 A JP2019518063 A JP 2019518063A JP 2019533442 A5 JP2019533442 A5 JP 2019533442A5
- Authority
- JP
- Japan
- Prior art keywords
- stem cells
- medium
- hours
- less
- storage medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000130 stem cell Anatomy 0.000 claims description 246
- 239000002609 media Substances 0.000 claims description 220
- 102000007562 Serum Albumin Human genes 0.000 claims description 150
- 108010071390 Serum Albumin Proteins 0.000 claims description 150
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 141
- 239000012595 freezing medium Substances 0.000 claims description 138
- 238000002360 preparation method Methods 0.000 claims description 112
- 210000004027 cells Anatomy 0.000 claims description 39
- 102100001249 ALB Human genes 0.000 claims description 37
- 101710027066 ALB Proteins 0.000 claims description 37
- 230000035939 shock Effects 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 238000004321 preservation Methods 0.000 claims description 30
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 claims description 27
- 229940116191 N-acetyltryptophan Drugs 0.000 claims description 27
- 239000003599 detergent Substances 0.000 claims description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 22
- 229940068968 Polysorbate 80 Drugs 0.000 claims description 21
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 21
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 21
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 21
- 229920000053 polysorbate 80 Polymers 0.000 claims description 21
- 230000004083 survival Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- 150000004665 fatty acids Chemical class 0.000 claims description 15
- 239000001963 growth media Substances 0.000 claims description 14
- 238000004113 cell culture Methods 0.000 claims description 13
- 239000000178 monomer Substances 0.000 claims description 13
- 229940050528 albumin Drugs 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 238000005138 cryopreservation Methods 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- 230000014759 maintenance of location Effects 0.000 claims description 10
- 125000005474 octanoate group Chemical class 0.000 claims description 10
- 238000004007 reversed phase HPLC Methods 0.000 claims description 10
- 229910052782 aluminium Inorganic materials 0.000 claims description 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 9
- 150000002402 hexoses Chemical class 0.000 claims description 9
- 210000002381 Plasma Anatomy 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 8
- 230000010261 cell growth Effects 0.000 claims description 8
- 230000035899 viability Effects 0.000 claims description 8
- 238000007710 freezing Methods 0.000 claims description 7
- 150000003278 haem Chemical class 0.000 claims description 7
- 239000002510 pyrogen Substances 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- 108010071241 Factor XIIa Proteins 0.000 claims description 6
- 229950008882 Polysorbate Drugs 0.000 claims description 6
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 6
- 238000004949 mass spectrometry Methods 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- 230000002335 preservative Effects 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 238000010257 thawing Methods 0.000 claims description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 6
- 108010062580 Concanavalin A Proteins 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 229940088597 Hormone Drugs 0.000 claims description 5
- 229940029983 VITAMINS Drugs 0.000 claims description 5
- 229940021016 Vitamin IV solution additives Drugs 0.000 claims description 5
- 150000001450 anions Chemical class 0.000 claims description 5
- 150000001768 cations Chemical class 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 229930003231 vitamins Natural products 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000000875 corresponding Effects 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 230000036252 glycation Effects 0.000 claims description 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006822 Human Serum Albumin Proteins 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 210000001519 tissues Anatomy 0.000 claims description 2
- 210000004748 cultured cells Anatomy 0.000 claims 3
- 208000006454 Hepatitis Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 description 16
- 235000021317 phosphate Nutrition 0.000 description 11
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- 239000000539 dimer Substances 0.000 description 8
- -1 gluconate ions Chemical class 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 230000003204 osmotic Effects 0.000 description 8
- 206010059512 Apoptosis Diseases 0.000 description 6
- 210000001185 Bone Marrow Anatomy 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 210000001778 pluripotent stem cell Anatomy 0.000 description 6
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-Aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 5
- 208000005176 Hepatitis C Diseases 0.000 description 5
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 5
- 150000001805 chlorine compounds Chemical class 0.000 description 5
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229940037179 Potassium Ion Drugs 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229940050410 gluconate Drugs 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- JLVVSXFLKOJNIY-UHFFFAOYSA-N magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 4
- 229910001425 magnesium ion Inorganic materials 0.000 description 4
- 230000003278 mimic Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- NPYPAHLBTDXSSS-UHFFFAOYSA-N potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 4
- 229910001414 potassium ion Inorganic materials 0.000 description 4
- FKNQFGJONOIPTF-UHFFFAOYSA-N sodium cation Chemical group [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 4
- 229910001415 sodium ion Inorganic materials 0.000 description 4
- 210000004504 Adult Stem Cells Anatomy 0.000 description 3
- 102000000412 Annexins Human genes 0.000 description 3
- 108050008874 Annexins Proteins 0.000 description 3
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 3
- 210000004700 Fetal Blood Anatomy 0.000 description 3
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 3
- 210000003494 Hepatocytes Anatomy 0.000 description 3
- 210000004263 Induced Pluripotent Stem Cells Anatomy 0.000 description 3
- 210000001178 Neural Stem Cells Anatomy 0.000 description 3
- 210000003954 Umbilical Cord Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002338 cryopreservative Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 210000001368 germline stem cell Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 210000002901 Mesenchymal Stem Cells Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000002107 myocardial Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 210000001612 Chondrocytes Anatomy 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108010056047 Prekallikrein Proteins 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003100 immobilizing Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002438 mitochondrial Effects 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000000790 osteoblast Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021128733A JP7249387B2 (ja) | 2016-10-04 | 2021-08-05 | 組換え酵母由来血清アルブミンの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16192276.0 | 2016-10-04 | ||
| EP16192276 | 2016-10-04 | ||
| PCT/EP2017/075257 WO2018065491A1 (en) | 2016-10-04 | 2017-10-04 | Uses of recombinant yeast-derived serum albumin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128733A Division JP7249387B2 (ja) | 2016-10-04 | 2021-08-05 | 組換え酵母由来血清アルブミンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019533442A JP2019533442A (ja) | 2019-11-21 |
| JP2019533442A5 true JP2019533442A5 (xx) | 2021-03-25 |
| JP6928084B2 JP6928084B2 (ja) | 2021-09-01 |
Family
ID=57047137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518063A Active JP6928084B2 (ja) | 2016-10-04 | 2017-10-04 | 組換え酵母由来血清アルブミンの使用 |
| JP2021128733A Active JP7249387B2 (ja) | 2016-10-04 | 2021-08-05 | 組換え酵母由来血清アルブミンの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128733A Active JP7249387B2 (ja) | 2016-10-04 | 2021-08-05 | 組換え酵母由来血清アルブミンの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190216079A1 (xx) |
| EP (3) | EP3429345B1 (xx) |
| JP (2) | JP6928084B2 (xx) |
| KR (2) | KR102662031B1 (xx) |
| CA (1) | CA3038422A1 (xx) |
| DK (1) | DK3429345T3 (xx) |
| ES (1) | ES2761854T3 (xx) |
| WO (1) | WO2018065491A1 (xx) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7437385B2 (ja) | 2018-09-06 | 2024-02-22 | バヴァリアン・ノルディック・アクティーゼルスカブ | 保管が改善されたポックスウイルス組成物 |
| KR20220031555A (ko) | 2019-06-11 | 2022-03-11 | 옥소젠 코포레이션 | 조직의 습식 보존 |
| EP4069200A1 (en) | 2019-12-04 | 2022-10-12 | Albumedix Ltd | Methods and compositions produced thereby |
| AU2021233167A1 (en) | 2020-03-12 | 2022-09-22 | Bavarian Nordic A/S | Compositions improving poxvirus stability |
| CN113549653B (zh) * | 2020-04-23 | 2024-03-22 | 上海赛比曼生物科技有限公司 | 用于慢病毒载体长期存贮的组合试剂 |
| JP7280623B2 (ja) * | 2020-12-28 | 2023-05-24 | 株式会社アビー | 細胞凍結保存液、及び細胞凍結方法 |
| JP7318983B2 (ja) * | 2021-12-21 | 2023-08-01 | 株式会社アビー | 細胞凍結保存液、及び細胞凍結方法 |
| WO2024018452A1 (en) | 2022-07-18 | 2024-01-25 | Yeda Research And Development Co. Ltd. | Albumin protein variants, production thereof and uses of same |
| CN117783501B (zh) * | 2024-02-26 | 2024-05-10 | 四川大学华西第二医院 | 辛酸钠在注意缺陷与多动障碍中的应用及产品 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| JP4798833B2 (ja) | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | 加熱処理工程を含むヒト血清アルブミンの製造方法 |
| WO2002034785A1 (fr) | 2000-10-24 | 2002-05-02 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Procede de monomerisation de polymeres d"albumine serique humaine |
| JP4798832B2 (ja) | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | ヒト血清アルブミン多量体の除去方法 |
| JP2004238392A (ja) * | 2003-01-14 | 2004-08-26 | Nipro Corp | 安定化された蛋白質性製剤 |
| GB0310347D0 (en) | 2003-05-07 | 2003-06-11 | Delta Biotechnology Ltd | Assay |
| DK1710250T3 (da) | 2004-01-20 | 2009-07-06 | Chemo Sero Therapeut Res Inst | Fremgangsmåde til fremstilling af humanserumalbumin ved varnebehandling i tilstedeværelse af divalt kation |
| JP5936112B2 (ja) | 2009-02-11 | 2016-06-15 | アルブミディクス アクティーゼルスカブ | アルブミン変異体及び複合体 |
| DK2427486T3 (en) * | 2009-05-07 | 2015-05-26 | Novozymes Biopharma Dk As | A process for purifying albumin |
| CA2776241A1 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
| WO2011075686A2 (en) * | 2009-12-18 | 2011-06-23 | Ventria Bioscience | Methods & compositions comprising heat shock proteins |
| SG182618A1 (en) * | 2010-01-25 | 2012-08-30 | Ventria Bioscience | Methods & compositions for improving protein production |
| WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
| CA2838964C (en) | 2011-07-05 | 2021-07-13 | Novozymes Biopharma Dk A/S | Albumin formulation and use |
| US9458424B2 (en) * | 2013-12-19 | 2016-10-04 | FertiPro N.V. | Methods for cryopreservation of stem cells via slow-freezing |
-
2017
- 2017-10-04 ES ES17786853T patent/ES2761854T3/es active Active
- 2017-10-04 KR KR1020237029284A patent/KR102662031B1/ko active IP Right Grant
- 2017-10-04 EP EP17786853.6A patent/EP3429345B1/en active Active
- 2017-10-04 EP EP20189314.6A patent/EP3791719A1/en active Pending
- 2017-10-04 JP JP2019518063A patent/JP6928084B2/ja active Active
- 2017-10-04 CA CA3038422A patent/CA3038422A1/en active Pending
- 2017-10-04 KR KR1020197010505A patent/KR102573478B1/ko active IP Right Grant
- 2017-10-04 WO PCT/EP2017/075257 patent/WO2018065491A1/en active Application Filing
- 2017-10-04 DK DK17786853T patent/DK3429345T3/da active
- 2017-10-04 EP EP19182203.0A patent/EP3603391A1/en not_active Withdrawn
-
2019
- 2019-04-02 US US16/372,581 patent/US20190216079A1/en active Pending
-
2021
- 2021-08-05 JP JP2021128733A patent/JP7249387B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533442A5 (xx) | ||
| KR102502294B1 (ko) | 세포 생존능력을 유지시키기 위한 조성물 및 방법 | |
| JP6850360B2 (ja) | 臨床使用可能な細胞凍結保存液 | |
| Blanco et al. | Comparative cryopreservation of avian spermatozoa: Benefits of non-permeating osmoprotectants and ATP on turkey and crane sperm cryosurvival | |
| JP6928084B2 (ja) | 組換え酵母由来血清アルブミンの使用 | |
| JP6957615B2 (ja) | 糖脂質による細胞凍結保存性の向上 | |
| US5543316A (en) | Injectable culture medium for maintaining viability of myoblast cells | |
| RU2396748C2 (ru) | Среда для хранения клеток | |
| RU2008137634A (ru) | Способ уменьшения агрегации белка | |
| EP2536823A1 (en) | Methods of manufacture of immunocompatible chorionic membrane products | |
| Boonkusol et al. | Effects of extender and storage time on motility and ultrastructure of cooled-preserved boar spermatozoa | |
| IL46257A (en) | Process for preserving elk semen by freezing | |
| WO2011147118A1 (zh) | 无蛋白非程序细胞冻存液 | |
| JP2006230396A (ja) | 細胞保存液 | |
| EP3294356A1 (en) | Compositions comprising mesenchymal stem cells and uses thereof | |
| JP2009219376A (ja) | 医療用細胞の保護用液 | |
| WO2004084629A1 (fr) | Procede de lyophilisation et de cryoconservation de cals et cryoprotecteur utilise | |
| US20100278934A1 (en) | Methods and compositions for conserving and/or preparing an organ or tissue for transplant | |
| KR102235332B1 (ko) | 중간엽줄기세포의 조정 배지 유래 엑소좀을 유효성분으로 포함하는 개과 동물의 정액 동결보존용 조성물 | |
| JP2023506132A (ja) | 大きな組織サンプルの無氷ガラス化およびナノ加温 | |
| Sui et al. | Ice-free cryopreservation of heart valve tissue: The effect of adding MitoQ to a VS83 formulation and its influence on mitochondrial dynamics | |
| KR20160018950A (ko) | 식물 유래 재조합 인간 혈청 알부민 및 식물성 펩타이드를 유효성분으로 함유하는 세포 보존용 조성물 | |
| WO2020033959A1 (en) | Cryopreservation medium for umbilical cord mscs derived from wharton's jelly | |
| CA3198837A1 (en) | Minimizing immunogenicity of decellularized tissues | |
| WO2021183653A1 (en) | Compositions for extending viable preservation and shelf-life of organs and tissues |